Upcoming Radio Show: The Latest in AML Treatment Advances: Where We Are and Where We're Going with James Blachly, MD, Ohio State University, Oct 25 @ 2 PM CST
Upcoming Radio Show: The Latest in AML Treatment Advances: Where We Are and Where We're Going with James Blachly, MD, Ohio State University, Oct 25 @ 2 PM CST
Posted Oct 18, 2021

This show will take place Monday, October 25th, 2021 @ 12 PM Pacific, 1 PM Mountain, 2 PM Central, 3 PM Eastern


Register here for the radio show


Call in by phone to listen live: (515) 602-9728 OR listen live via computer


Radio Show Description

Progress in understanding AML and developing therapies that treat this blood cancer is occurring at an astounding pace. In this radio show, Dr. James Blachly, an AML expert from the James Comprehensive Cancer Center at Ohio State University will share a comprehensive overview of the latest treatments for all stages of AML. Dr. Blachly will discuss combination therapies, new immunotherapies, new diagnostic technologies and new targeted treatments that are being used in the clinic today and in development in AML clinical trials. Dr. Blachly will simplify the significant work being performed all over the world by dedicated researchers who have the goal of finding a cure for all patients with AML.

Dr. Blachly's Bio

Dr. Blachly's practice consists of treating patients with acute myeloid leukemia along with other leukemias such as hairy cell leukemia, CLL and ALL within the hematology and transplantation clinic at the Ohio State University James Comprehensive Cancer Center in Columbus, Ohio. His current research conducted within the Blachly Lab focuses on understanding the role genetics and genomics play in the development, progression and treatment of acute myeloid leukemia and chronic lymphocytic leukemia, and returning that information back to the clinic, informing the design of future clinical trials to improve patient care. 

As a complement to his clinical and research roles, Dr. Blachly is also an Assistant Professor of Biomedical Informatics and Internal Medicine at Ohio State University.

Dr. Blachly currently serves as co-chair for the Alliance for Clinical Trials in Oncology and co-chair elect for the Alliance for Clinical Trials in Oncology Translational Informatics Committee. He holds memberships with the American Society of Clinical Oncology, American Society of Hematology and the Society of Hematologic Oncology.

He is currently participating in several AML clinical trials including a phase 1b study of venetoclax and dinaciclib (MK7965) in patients with relapsed/refractory AML, a phase 1b/2 study of pinometostat in combination with standard induction chemotherapy in newly diagnosed AML with MLL rearrangement and a phase 1/1b/2a, 3-part open-label multicenter study looking at the use of AZD5991 monotherapy and in combination with venetoclax in relapsed/refractory blood cancers.

You definitely don't want to miss this show! If you can't attend live, we encourage you to still register as the recording will be sent out to everyone who registers after the event.

Register here for the radio show

Thanks to our episode sponsor, Amgen

The author Katie Braswell

about the author
Katie Braswell

Katie joined the HealthTree Foundation as the Community Director for AML in 2021. She is a registered dietitian who previously worked at the VA hospital in Dallas, Texas where she coached veterans with blood cancer on how to use nutrition to improve their treatment outcomes and minimize cancer-related side effects. Katie is passionate about health education and patient empowerment. In her spare time, she loves to experiment with new recipes in the kitchen, spend time running outdoors and travel to new places.

More HealthTree Radio for AML Articles

Article Image Full Radio Show: The Latest in AML Treatment Advances: Where We Are and Where We're Going with James Blachly, MD, Ohio State University Article Image Full Radio Show: Harnessing the Immune System in Relapsed/Refractory AML with Dr. John Reagan, Rhode Island Hospital Article Image Full Radio Show: The Advancement of Treatment Options for Older Adults with AML with Gabriel Mannis, MD, Stanford Cancer Institute

Get the latest thought leadership on AML delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for AML Newsletter" for AML news, life with AML stories, AML clinical trials, AML 101 articles and events with AML experts.

Thanks to our HealthTree Community for AML Sponsors:

Follow Us

facebook instagram twitter youtube


Terms of Use and Privacy Policy     Newsroom     About    Donations    Find an AML Specialist     Newsletter     Learn     Connect


Copyright © 2021 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / HealthTree for AML is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811